Factory Supply High Quality Azithromycin Powder CAS. 83905-01-5 99% Purity

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: Azithromycin
• CAS: 83905-01-5
• Grade Standard: Medicine Grade
• Mf: C38h72n2o12
• MW: 748.98
• Transport Package: Bottle, Can, Drum, Plastic Container, Vacuum Packe
• Specification: Powder
• Trademark: Senwayer
• Origin: Wuhan, China
• HS Code: 3001200010
• Production Capacity: 1000kilograms Per Month

Product Description

Factory Supply High Quality Azithromycin Powder  CAS.83905-01-5 99% Purity

Product name	Azithromycin
CAS no.	83905-01-5
Molecular Formula	C38H72N2O12
Molecular Weight	748.98
Brand Name	Senwayer

Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.

1.Azithromycin is used to treat or prevent certain bacterial infections, most often those causing middle ear infections, strep throat, pneumonia, typhoid, and sinusitis;

2.It has been used primarily to prevent bacterial infections in infants and those with weaker immune system;

3.It is also effective against certain sexually transmitted infections, such as non- gonococcal urethritis, chlamydia, and cervicitis;

4.Azithromycin is used for acute pharyngitis, acute tonsillitis caused by Streptococcus pyogenes;

5.Azithromycin is used for acute throat and tonsillitis which are caused by streptococcus pyogenes, otitis;

6.Azithromycin can treatment of media sinusitis acute bronchitis skin soft tissue infection which are caused by sensitive bacteria;

7.Azithromycin is also used for pneumonia urethritis cervicitis and so on.

 

To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.